-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $88

Benzinga·05/01/2026 17:36:31
Listen to the news
Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $73 to $88.